Table: Sumitomo Pharma -2025/26 group results (IFRS)

Sumitomo Pharma

13/05/2026 05:00

May 13 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                 Year ended      Year ended       Year to        NEXT  
              Mar 31, 2026    Mar 31, 2025   Mar 31, 2027      YEAR    
                 LATEST         YEAR-AGO        COMPANY      COMPANY   
                 RESULTS         RESULT        FORECAST    H1 FORECAST 
  Sales          453.29          398.83         540.00                 
               (+13.7 pct)     (+26.8 pct)    (+19.1 pct)              
  Operating      107.34           28.80          90.00                 
              (+272.6 pct)                    (-16.2 pct)              
  Pretax
  Net            106.87           23.63          77.00                 
              (+352.2 pct)                    (-27.9 pct)              
  EPS Basic    268.99 yen       59.49 yen     172.89 yen               
  Ann Div          NIL             NIL                                 
  -Q2 Div          NIL             NIL                                 
  -Q4 Div          NIL             NIL                                 
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T